Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine versus bromhexine in acute exacerbation of COPD
IRCT20120215009014N580Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of acetylcysteine and bromhexine in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Change in clinical symptoms during acute exacerbation. Started Nov 2025; status: completed.
02
Drugs
acetylcysteinebromhexine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on IRCT20120215009014N580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N580.